Xi G, Hua Y, Keep R F, Duong H K, Hoff J T
Department of Surgery, University of Michigan, Ann Arbor, MI 48109-0532, USA.
Brain Res. 2001 Mar 23;895(1-2):153-9. doi: 10.1016/s0006-8993(01)02064-9.
Our recent studies have shown that prior intracerebral injection of a low dose of thrombin attenuates the brain edema formation that results from either an intracerebral hematoma, an intracerebral injection of a large dose of thrombin or cerebral ischemia. The aim of the current study is to investigate whether thrombin-induced tolerance (thrombin preconditioning; TPC) is associated with activation of p44/42 mitogen activated protein (MAP) kinases.
This study contained three parts. In the first, rats received an intracerebral infusion of either saline or one unit thrombin (the TPC dose) into the right caudate nucleus. After 1, 3 and 7 days, the rats will be killed and brains used to detect p44/42 MAP kinases activation using Western blot analysis and immunohistochemistry. In the second and third parts, rats received intracerebral infusions of either vehicle, one unit thrombin (TPC) or one unit thrombin and 5 nmol PD 098059. These rats were either killed to detect kinases activation after 24 h or received a second intracerebral infusion of five-unit thrombin 7 days later with brain edema being assessed after a further 24 h.
Western blot analysis demonstrated that p44/42 MAP kinases were activated in the ipsilateral basal ganglia after the intracerebral infusion of thrombin one unit. Cells immunoreactive for activated p44/42 MAP kinases were found in the ipsilateral basal ganglia and ipsilateral cortex. PD 098059, a MAP kinase kinase inhibitor, abolished thrombin-induced activation of p44/42 MAP kinases. TPC suppressed thrombin-induced brain edema while PD 098059 blocked this protective effect. The water contents in the ipsilateral basal ganglia 24 h after infusion of thrombin five units were 82.6+/-0.8%, 79.2+/-0.4% and 81.8+/-1.9% in the control, TPC alone and TPC plus PD 098059 groups, respectively.
Thrombin can activate p44/42 MAP kinases within the brain and the protective effects of thrombin preconditioning on brain edema formation are related to this activation.
我们最近的研究表明,预先脑内注射低剂量凝血酶可减轻因脑内血肿、脑内注射大剂量凝血酶或脑缺血所致的脑水肿形成。本研究的目的是探讨凝血酶诱导的耐受性(凝血酶预处理;TPC)是否与p44/42丝裂原活化蛋白(MAP)激酶的激活有关。
本研究包含三个部分。第一部分,大鼠右侧尾状核脑内分别注入生理盐水或1单位凝血酶(TPC剂量)。1、3和7天后,处死大鼠,取脑,采用蛋白质免疫印迹分析和免疫组织化学检测p44/42 MAP激酶的激活情况。第二和第三部分,大鼠脑内分别注入溶剂、1单位凝血酶(TPC)或1单位凝血酶加5 nmol PD 098059。这些大鼠在24小时后处死以检测激酶激活情况,或在7天后再次脑内注入5单位凝血酶,再过24小时后评估脑水肿情况。
蛋白质免疫印迹分析表明,脑内注入1单位凝血酶后,同侧基底神经节中p44/42 MAP激酶被激活。在同侧基底神经节和同侧皮质中发现了对活化p44/42 MAP激酶呈免疫反应的细胞。MAP激酶激酶抑制剂PD 098059可消除凝血酶诱导的p44/42 MAP激酶激活。TPC可抑制凝血酶诱导的脑水肿,而PD 098059可阻断这种保护作用。注入5单位凝血酶24小时后,对照组、单纯TPC组和TPC加PD 098059组同侧基底神经节的含水量分别为82.6±0.8%、79.2±0.4%和81.8±1.9%。
凝血酶可激活脑内的p44/42 MAP激酶,凝血酶预处理对脑水肿形成的保护作用与此激活有关。